4dri › Citations

Large FK506-binding proteins shape the pharmacology of rapamycin.

März AM, Fabian AK, Kozany C, Bracher A, Hausch F
Mol Cell Biol 33 1357-67 (2013)
Related entries: 4drh, 4drj

Cited: 81 times
EuropePMC logo PMID: 23358420

Abstract

The immunosuppressant and anticancer drug rapamycin works by inducing inhibitory protein complexes with the kinase mTOR, an important regulator of growth and proliferation. The obligatory accessory partner of rapamycin is believed to be FK506-binding protein 12 (FKBP12). Here we show that rapamycin complexes of larger FKBP family members can tightly bind to mTOR and potently inhibit its kinase activity. Cocrystal structures with FKBP51 and FKBP52 reveal the modified molecular binding mode of these alternative ternary complexes in detail. In cellular model systems, FKBP12 can be functionally replaced by larger FKBPs. When the rapamycin dosage is limiting, mTOR inhibition of S6K phosphorylation can be enhanced by FKBP51 overexpression in mammalian cells, whereas FKBP12 is dispensable. FKBP51 could also enable the rapamycin-induced hyperphosphorylation of Akt, which depended on higher FKBP levels than rapamycin-induced inhibition of S6K phosphorylation. These insights provide a mechanistic rationale for preferential mTOR inhibition in specific cell or tissue types by engaging specific FKBP homologs.

Reviews - 4dri mentioned but not cited (3)

  1. Roles of Prolyl Isomerases in RNA-Mediated Gene Expression. Thapar R. Biomolecules 5 974-999 (2015)
  2. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. Nussinov R, Zhang M, Maloney R, Liu Y, Tsai CJ, Jang H. J Mol Biol 434 167569 (2022)
  3. Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches. Shanak S, Bassalat N, Barghash A, Kadan S, Ardah M, Zaid H. Evid Based Complement Alternat Med 2022 2832889 (2022)

Articles - 4dri mentioned but not cited (22)

  1. Principles of self-organization and load adaptation by the actin cytoskeleton during clathrin-mediated endocytosis. Akamatsu M, Vasan R, Serwas D, Ferrin MA, Rangamani P, Drubin DG. Elife 9 e49840 (2020)
  2. FKBPs and the Akt/mTOR pathway. Hausch F, Kozany C, Theodoropoulou M, Fabian AK. Cell Cycle 12 2366-2370 (2013)
  3. Why Some Targets Benefit from beyond Rule of Five Drugs. Egbert M, Whitty A, Keserű GM, Vajda S. J Med Chem 62 10005-10025 (2019)
  4. Combined x-ray crystallography and computational modeling approach to investigate the Hsp90 C-terminal peptide binding to FKBP51. Kumar R, Moche M, Winblad B, Pavlov PF. Sci Rep 7 14288 (2017)
  5. Protein-protein interfaces are vdW dominant with selective H-bonds and (or) electrostatics towards broad functional specificity. Nilofer C, Sukhwal A, Mohanapriya A, Kangueane P. Bioinformation 13 164-173 (2017)
  6. New Mammalian Target of Rapamycin (mTOR) Modulators Derived from Natural Product Databases and Marine Extracts by Using Molecular Docking Techniques. Ruiz-Torres V, Losada-Echeberría M, Herranz-López M, Barrajón-Catalán E, Galiano V, Micol V, Encinar JA. Mar Drugs 16 E385 (2018)
  7. ACTP: A webserver for predicting potential targets and relevant pathways of autophagy-modulating compounds. Xie T, Zhang L, Zhang S, Ouyang L, Cai H, Liu B. Oncotarget 7 10015-10022 (2016)
  8. Crystal structure of the FK506 binding domain of human FKBP25 in complex with FK506. Prakash A, Rajan S, Yoon HS. Protein Sci 25 905-910 (2016)
  9. Design, synthesis and pharmaco-toxicological assessment of 5-mercapto-1,2,4-triazole derivatives with antibacterial and antiproliferative activity. Mioc M, Soica C, Bercean V, Avram S, Balan-Porcarasu M, Coricovac D, Ghiulai R, Muntean D, Andrica F, Dehelean C, Spandidos DA, Tsatsakis AM, Kurunczi L. Int J Oncol 50 1175-1183 (2017)
  10. In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors. Zulkipli NN, Zakaria R, Long I, Abdullah SF, Muhammad EF, Wahab HA, Sasongko TH. Molecules 25 E3991 (2020)
  11. A new cytotoxic polycyclic polyprenylated acylphloroglucinol from Garcinia nujiangensis screened by the LC-PDA and LC-MS. Tang Z, Lu L, Zhou X, Shen J, Song W, Tang Y, Xia Z. Nat Prod Res 34 2448-2455 (2020)
  12. Adaptive laboratory evolution in S. cerevisiae highlights role of transcription factors in fungal xenobiotic resistance. Ottilie S, Luth MR, Hellemann E, Goldgof GM, Vigil E, Kumar P, Cheung AL, Song M, Godinez-Macias KP, Carolino K, Yang J, Lopez G, Abraham M, Tarsio M, LeBlanc E, Whitesell L, Schenken J, Gunawan F, Patel R, Smith J, Love MS, Williams RM, McNamara CW, Gerwick WH, Ideker T, Suzuki Y, Wirth DF, Lukens AK, Kane PM, Cowen LE, Durrant JD, Winzeler EA. Commun Biol 5 128 (2022)
  13. Study on the Mechanism of Üstikuddus Sherbiti in Ischemic Cerebrovascular Diseases: Based on Network Pharmacology. Gul A, Aimaiti M, Tuerxun T, Amat R, Reheman A, Zhang MF, Memtily N. Evid Based Complement Alternat Med 2022 5581864 (2022)
  14. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  15. Carica Papaya Reduces High Fat Diet and Streptozotocin-Induced Development of Inflammation in Adipocyte via IL-1β/IL-6/TNF-α Mediated Signaling Mechanisms in Type-2 Diabetic Rats. Rebecca Roy J, Janaki CS, Jayaraman S, Periyasamy V, Balaji T, Vijayamalathi M, Veeraraghavan VP, Krishnamoorthy K, Prasad M. Curr Issues Mol Biol 45 852-884 (2023)
  16. Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer. Herrera-Calderon O, Yepes-Pérez AF, Quintero-Saumeth J, Rojas-Armas JP, Palomino-Pacheco M, Ortiz-Sánchez JM, Cieza-Macedo EC, Arroyo-Acevedo JL, Figueroa-Salvador L, Peña-Rojas G, Andía-Ayme V. Evid Based Complement Alternat Med 2020 8830665 (2020)
  17. Cryo-EM reveals how Hsp90 and FKBP immunophilins co-regulate the glucocorticoid receptor. Noddings CM, Johnson JL, Agard DA. Nat Struct Mol Biol 30 1867-1877 (2023)
  18. Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer. Huang B, Wen G, Li R, Wu M, Zou Z. Medicine (Baltimore) 102 e35070 (2023)
  19. Kinesin-1 transports morphologically distinct intracellular virions during vaccinia infection. Xu A, Basant A, Schleich S, Newsome TP, Way M. J Cell Sci 136 jcs260175 (2023)
  20. Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy. Zhao J, Liu H, Xia M, Chen Q, Wan L, Leng B, Tang C, Chen G, Liu Y, Zhang L, Liu H. Drug Des Devel Ther 17 887-900 (2023)
  21. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer. Kong D, Ye C, Zhang C, Sun X, Wang F, Chen R, Xiao G, He S, Xu J, Rao X, Ai J, Gao X, Li H, Su L. J Exp Clin Cancer Res 42 45 (2023)
  22. TB-IECS: an accurate machine learning-based scoring function for virtual screening. Zhang X, Shen C, Jiang D, Zhang J, Ye Q, Xu L, Hou T, Pan P, Kang Y. J Cheminform 15 63 (2023)


Reviews citing this publication (16)

  1. Interventions to Slow Aging in Humans: Are We Ready? Longo VD, Antebi A, Bartke A, Barzilai N, Brown-Borg HM, Caruso C, Curiel TJ, de Cabo R, de Cabo R, Franceschi C, Gems D, Ingram DK, Johnson TE, Kennedy BK, Kenyon C, Klein S, Kopchick JJ, Lepperdinger G, Madeo F, Mirisola MG, Mitchell JR, Passarino G, Rudolph KL, Sedivy JM, Shadel GS, Sinclair DA, Spindler SR, Suh Y, Vijg J, Vinciguerra M, Fontana L. Aging Cell 14 497-510 (2015)
  2. Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism. Zannas AS, Binder EB. Genes Brain Behav 13 25-37 (2014)
  3. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nanthakumar CB, Hatley RJ, Lemma S, Gauldie J, Marshall RP, Macdonald SJ. Nat Rev Drug Discov 14 693-720 (2015)
  4. FKBP Ligands-Where We Are and Where to Go? Kolos JM, Voll AM, Bauder M, Hausch F. Front Pharmacol 9 1425 (2018)
  5. Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds. Dunyak BM, Gestwicki JE. J Med Chem 59 9622-9644 (2016)
  6. The Many Faces of FKBP51. Hähle A, Merz S, Meyners C, Hausch F. Biomolecules 9 E35 (2019)
  7. Next Generation Strategies for Geroprotection via mTORC1 Inhibition. Dumas SN, Lamming DW. J Gerontol A Biol Sci Med Sci 75 14-23 (2020)
  8. Focus on FKBP51: A molecular link between stress and metabolic disorders. Häusl AS, Balsevich G, Gassen NC, Schmidt MV. Mol Metab 29 170-181 (2019)
  9. Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease. Rostam MA, Piva TJ, Rezaei HB, Kamato D, Little PJ, Zheng W, Osman N. Clin Exp Pharmacol Physiol 42 117-124 (2015)
  10. The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics". Ciocan-Cartita CA, Jurj A, Buse M, Gulei D, Braicu C, Raduly L, Cojocneanu R, Pruteanu LL, Iuga CA, Coza O, Berindan-Neagoe I. Int J Mol Sci 20 E2576 (2019)
  11. FK506-binding protein 12 ligands: a patent review. Liu F, Wang YQ, Meng L, Gu M, Tan RY. Expert Opin Ther Pat 23 1435-1449 (2013)
  12. Regulation of the Target of Rapamycin and Other Phosphatidylinositol 3-Kinase-Related Kinases by Membrane Targeting. De Cicco M, Rahim MS, Dames SA. Membranes (Basel) 5 553-575 (2015)
  13. Conformational Dynamics in FKBP Domains: Relevance to Molecular Signaling and Drug Design. LeMaster DM, Hernandez G. Curr Mol Pharmacol 9 5-26 (2015)
  14. Analysis of the Selective Antagonist SAFit2 as a Chemical Probe for the FK506-Binding Protein 51. Buffa V, Knaup FH, Heymann T, Springer M, Schmidt MV, Hausch F. ACS Pharmacol Transl Sci 6 361-371 (2023)
  15. Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities. Galat A. Biomolecules 7 E72 (2017)
  16. Molecular chameleons in drug discovery. Poongavanam V, Wieske LHE, Peintner S, Erdélyi M, Kihlberg J. Nat Rev Chem 8 45-60 (2024)

Articles citing this publication (40)

  1. Selective inhibitors of the FK506-binding protein 51 by induced fit. Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C, Zannas AS, Draenert R, Binder EB, Almeida OF, Rühter G, Uhr M, Schmidt MV, Touma C, Bracher A, Hausch F. Nat Chem Biol 11 33-37 (2015)
  2. A new protein-protein interaction sensor based on tripartite split-GFP association. Cabantous S, Nguyen HB, Pedelacq JD, Koraïchi F, Chaudhary A, Ganguly K, Lockard MA, Favre G, Terwilliger TC, Waldo GS. Sci Rep 3 2854 (2013)
  3. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, Kennedy BK. Aging Cell 14 265-273 (2015)
  4. A novel rapamycin analog is highly selective for mTORC1 in vivo. Schreiber KH, Arriola Apelo SI, Yu D, Brinkman JA, Velarde MC, Syed FA, Liao CY, Baar EL, Carbajal KA, Sherman DS, Ortiz D, Brunauer R, Yang SE, Tzannis ST, Kennedy BK, Lamming DW. Nat Commun 10 3194 (2019)
  5. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Mol Cancer Ther 15 1557-1567 (2016)
  6. InterAKTions with FKBPs--mutational and pharmacological exploration. Fabian AK, März A, Neimanis S, Biondi RM, Kozany C, Hausch F. PLoS One 8 e57508 (2013)
  7. Crystal structures of the free and ligand-bound FK1-FK2 domain segment of FKBP52 reveal a flexible inter-domain hinge. Bracher A, Kozany C, Hähle A, Wild P, Zacharias M, Hausch F. J Mol Biol 425 4134-4144 (2013)
  8. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface. Shigdel UK, Lee SJ, Sowa ME, Bowman BR, Robison K, Zhou M, Pua KH, Stiles DT, Blodgett JAV, Udwary DW, Rajczewski AT, Mann AS, Mostafavi S, Hardy T, Arya S, Weng Z, Stewart M, Kenyon K, Morgenstern JP, Pan E, Gray DC, Pollock RM, Fry AM, Klausner RD, Townson SA, Verdine GL. Proc Natl Acad Sci U S A 117 17195-17203 (2020)
  9. PI3K inhibitors protect against glucocorticoid-induced skin atrophy. Agarwal S, Mirzoeva S, Readhead B, Dudley JT, Budunova I. EBioMedicine 41 526-537 (2019)
  10. The Hsp90 machinery facilitates the transport of diphtheria toxin into human cells. Schuster M, Schnell L, Feigl P, Birkhofer C, Mohr K, Roeder M, Carle S, Langer S, Tippel F, Buchner J, Fischer G, Hausch F, Frick M, Schwan C, Aktories K, Schiene-Fischer C, Barth H. Sci Rep 7 613 (2017)
  11. Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy. Baida G, Bhalla P, Yemelyanov A, Stechschulte LA, Shou W, Readhead B, Dudley JT, Sánchez ER, Budunova I. Oncotarget 9 34772-34783 (2018)
  12. Proximity-Directed Labeling Reveals a New Rapamycin-Induced Heterodimer of FKBP25 and FRB in Live Cells. Lee SY, Lee H, Lee HK, Lee SW, Ha SC, Kwon T, Seo JK, Lee C, Rhee HW. ACS Cent Sci 2 506-516 (2016)
  13. Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Posada IMD, Lectez B, Sharma M, Oetken-Lindholm C, Yetukuri L, Zhou Y, Aittokallio T, Abankwa D. Oncotarget 8 44550-44566 (2017)
  14. Transcriptomic analysis of crustacean molting gland (Y-organ) regulation via the mTOR signaling pathway. Shyamal S, Das S, Guruacharya A, Mykles DL, Durica DS. Sci Rep 8 7307 (2018)
  15. Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway. Sun P, Wang Y, Ding Y, Luo J, Zhong J, Xu N, Zhang Y, Xie W. iScience 24 102521 (2021)
  16. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. Shi G, Chiramel AI, Li T, Lai KK, Kenney AD, Zani A, Eddy AC, Majdoul S, Zhang L, Dempsey T, Beare PA, Kar S, Yewdell JW, Best SM, Yount JS, Compton AA. J Clin Invest 132 e160766 (2022)
  17. Structural basis of conformational transitions in the active site and 80's loop in the FK506-binding protein FKBP12. Mustafi SM, Brecher M, Zhang J, Li H, Lemaster DM, Hernández G. Biochem J 458 525-536 (2014)
  18. Differential conformational dynamics in the closely homologous FK506-binding domains of FKBP51 and FKBP52. Mustafi SM, LeMaster DM, Hernández G. Biochem J 461 115-123 (2014)
  19. PCB 95 promotes dendritic growth in primary rat hippocampal neurons via mTOR-dependent mechanisms. Keil KP, Miller GW, Chen H, Sethi S, Schmuck MR, Dhakal K, Kim JW, Lein PJ. Arch Toxicol 92 3163-3173 (2018)
  20. Rational design and asymmetric synthesis of potent and neurotrophic ligands for FK506-binding proteins (FKBPs). Pomplun S, Wang Y, Kirschner A, Kozany C, Bracher A, Hausch F. Angew Chem Int Ed Engl 54 345-348 (2015)
  21. Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease. Lee C, Guo H, Klinngam W, Janga SR, Yarber F, Peddi S, Edman MC, Tiwari N, Liu S, Louie SG, Hamm-Alvarez SF, MacKay JA. Mol Pharm 16 3024-3039 (2019)
  22. Two crystal structures of the FK506-binding domain of Plasmodium falciparum FKBP35 in complex with rapamycin at high resolution. Bianchin A, Allemand F, Bell A, Chubb AJ, Guichou JF. Acta Crystallogr D Biol Crystallogr 71 1319-1327 (2015)
  23. Macrocyclic FKBP51 Ligands Define a Transient Binding Mode with Enhanced Selectivity. Voll AM, Meyners C, Taubert MC, Bajaj T, Heymann T, Merz S, Charalampidou A, Kolos J, Purder PL, Geiger TM, Wessig P, Gassen NC, Bracher A, Hausch F. Angew Chem Int Ed Engl 60 13257-13263 (2021)
  24. Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51. Zhang J, Wu D, He Y, Li L, Liu S, Lu J, Gui H, Wang Y, Tao Y, Wang H, Kaushik D, Rodriguez R, Wang Z. Biochem Biophys Rep 23 100778 (2020)
  25. Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain. Anderson JS, Mustafi SM, Hernández G, LeMaster DM. Biophys Chem 192 41-48 (2014)
  26. FKBP25 participates in DNA double-strand break repair. Dilworth D, Gong F, Miller K, Nelson CJ. Biochem Cell Biol 98 42-49 (2020)
  27. C-H…O hydrogen bonds in FK506-binding protein-ligand interactions. Rajan S, Baek K, Yoon HS. J Mol Recognit 26 550-555 (2013)
  28. FK506-Binding Protein 5 mRNA Levels in Ileal Mucosa Are Associated with Pouchitis in Patients with Ulcerative Colitis. Araki T, Kawamura M, Tanaka K, Okita Y, Fujikawa H, Uchida K, Toiyama Y, Inoue Y, Mohri Y, Kusunoki M. Dig Dis Sci 60 1617-1623 (2015)
  29. FKBP51 and FKBP12.6-Novel and tight interactors of Glomulin. Hähle A, Geiger TM, Merz S, Meyners C, Tianqi M, Kolos J, Hausch F. PLoS One 14 e0221926 (2019)
  30. Reversion of glucocorticoid-induced senescence and collagen synthesis decrease by LY294002 is mediated through p38 in skin. Le QV, Wen SY, Chen CJ, Huang CY, Kuo WW. Int J Biol Sci 18 6102-6113 (2022)
  31. Tissue-restricted inhibition of mTOR using chemical genetics. Wassarman DR, Bankapalli K, Pallanck LJ, Shokat KM. Proc Natl Acad Sci U S A 119 e2204083119 (2022)
  32. Bioinformatic Analysis of Two TOR (Target of Rapamycin)-Like Proteins Encoded by Entamoeba histolytica Revealed Structural Similarities with Functional Homologs. Muñoz-Muñoz PLA, Mares-Alejandre RE, Meléndez-López SG, Ramos-Ibarra MA. Genes (Basel) 12 1139 (2021)
  33. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach. Rasul HO, Aziz BK, Ghafour DD, Kivrak A. Mol Divers 27 1141-1162 (2023)
  34. Early Life Stress, FKBP5 Polymorphisms, and Quantitative Glycemic Traits. Suarez A, Lahti J, Kajantie E, Eriksson JG, Räikkönen K. Psychosom Med 79 524-532 (2017)
  35. Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction. Rasul HO, Aziz BK, Ghafour DD, Kivrak A. Mol Divers (2022)
  36. The mechanistic target of rapamycin complex 1 critically regulates the function of mononuclear phagocytes and promotes cardiac remodeling in acute ischemia. Chen G, Phan V, Luo X, Cao DJ. J Mol Cell Cardiol 159 62-79 (2021)
  37. Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor. Artoni F, Grützmacher N, Demetriades C. Aging Cell 22 e13888 (2023)
  38. Ceg1 depletion reveals mechanisms governing degradation of non-capped RNAs in Saccharomyces cerevisiae. Zanin O, Eastham M, Winczura K, Ashe M, Martinez-Nunez RT, Hebenstreit D, Grzechnik P. Commun Biol 6 1112 (2023)
  39. Dissecting regulatory T cell expansion using polymer microparticles presenting defined ratios of self-antigen and regulatory cues. Bridgeman CJ, Shah SA, Oakes RS, Jewell CM. Front Bioeng Biotechnol 11 1184938 (2023)
  40. Synthesis, Characterization, and Preliminary In Vitro Cytotoxic Evaluation of a Series of 2-Substituted Benzo [d] [1,3] Azoles. Linares-Anaya O, Avila-Sorrosa A, Díaz-Cedillo F, Gil-Ruiz LÁ, Correa-Basurto J, Salazar-Mendoza D, Orjuela AL, Alí-Torres J, Ramírez-Apan MT, Morales-Morales D. Molecules 26 2780 (2021)


Quick links